Takeda Pharmaceutical Co Ltd (TAK)
13.62
+0.06
(+0.41%)
USD |
NYSE |
Nov 15, 16:00
13.62
0.00 (0.00%)
After-Hours: 20:00
Takeda Pharmaceutical Enterprise Value: 72.05B for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 72.05B |
| November 13, 2024 | 72.02B |
| November 12, 2024 | 71.96B |
| November 11, 2024 | 72.30B |
| November 08, 2024 | 72.72B |
| November 07, 2024 | 72.97B |
| November 06, 2024 | 72.75B |
| November 05, 2024 | 74.11B |
| November 04, 2024 | 73.57B |
| November 01, 2024 | 73.29B |
| October 31, 2024 | 73.22B |
| October 30, 2024 | 73.07B |
| October 29, 2024 | 72.94B |
| October 28, 2024 | 72.15B |
| October 25, 2024 | 72.05B |
| October 24, 2024 | 72.78B |
| October 23, 2024 | 72.97B |
| October 22, 2024 | 73.83B |
| October 21, 2024 | 73.89B |
| October 18, 2024 | 74.46B |
| October 17, 2024 | 74.24B |
| October 16, 2024 | 73.67B |
| October 15, 2024 | 73.57B |
| October 14, 2024 | 74.49B |
| October 11, 2024 | 74.37B |
| Date | Value |
|---|---|
| October 10, 2024 | 74.40B |
| October 09, 2024 | 74.30B |
| October 08, 2024 | 74.37B |
| October 07, 2024 | 74.46B |
| October 04, 2024 | 74.78B |
| October 03, 2024 | 74.17B |
| October 02, 2024 | 74.43B |
| October 01, 2024 | 74.30B |
| September 30, 2024 | 74.11B |
| September 27, 2024 | 74.82B |
| September 26, 2024 | 75.17B |
| September 25, 2024 | 74.95B |
| September 24, 2024 | 75.65B |
| September 23, 2024 | 75.93B |
| September 20, 2024 | 75.65B |
| September 19, 2024 | 76.06B |
| September 18, 2024 | 75.71B |
| September 17, 2024 | 75.81B |
| September 16, 2024 | 75.65B |
| September 13, 2024 | 75.33B |
| September 12, 2024 | 75.71B |
| September 11, 2024 | 75.71B |
| September 10, 2024 | 75.93B |
| September 09, 2024 | 75.90B |
| September 06, 2024 | 75.68B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.66B
Minimum
Oct 19 2022
107.09B
Maximum
Nov 19 2019
82.21B
Average
77.54B
Median
Enterprise Value Benchmarks
| HUTCHMED (China) Ltd | 2.171B |
| Astellas Pharma Inc | 23.34B |
| Nxera Pharma Co Ltd | 818.86M |
| PeptiDream Inc | 2.175B |
| Healios KK | 117.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 619.69M |
| Revenue (Quarterly) | 7.918B |
| Total Expenses (Quarterly) | 6.075B |
| EPS Diluted (Quarterly) | 0.1924 |
| Gross Profit Margin (Quarterly) | 66.47% |
| Profit Margin (Quarterly) | 7.83% |
| Earnings Yield | 4.44% |
| Operating Earnings Yield | 7.23% |
| Normalized Earnings Yield | 4.436 |